• Type:
  • Category:

BRAIN Biotech AG Financial Results H1 2022 / 23 | Steady Growth, Strategy, and Future Outlook with CFO

Share

BRAIN Biotech AG H1 2022/23: Key Takeaways

Impressive Half-Year Results by BRAIN Biotech AG

CFO Michael Schneiders shares the impressive half-year results for BRAIN Biotech AG for the 2022/2023 fiscal year in this comprehensive video presentation. This global leader in industrial biologization has remained on a steady growth path, demonstrating a 16.8% rise in revenue and a solid cash position of €9.2 million. BRAIN Biotech AG has also acquired full ownership of core asset Biocatalysts Ltd, signalling an accelerated strategy toward “One-BioProducts”.

 

Deep Dive into Achievements and Organisational Structure

The presentation deep-dives into their recent achievements and organisational structure, shedding light on consolidating its subsidiaries, Breatec B.V., Biosun Biochemicals Inc., and WeissBioTech GmbH, into Biocatalysts. The video discusses financial and business highlights, including the robust performance of different business segments, increased revenue, and the strategic development of their CRISPR technology platform, Akribion Genomics.

 

Investments and Initiatives in Biotechnology

Additionally, Schneiders details their ongoing investments and initiatives to leverage biotechnology’s power to create a global multi-niche enzyme champion. Overall, the video offers valuable insights into the company’s sustainable growth, solid financial position, and strategic vision for the future.

 

 

Chapters
  • BRAIN at a Glance
  • Sustainability: Manifold Business Opportunities
  • From Candidates to Industrial Production Processes
  • Business Highlights 6M 22/23
  • Efficient & Transparent Organization – H1 22/23
  • Financial Highlights 6M FY 2022/23 at a Glance
  • Cash & Cash Flow
  • Adjusted Ebitda
  • General Risk Factor Update
  • Our Targets – Confirmed
Resources
Presentation
BRAIN Biotech Video Hub
Podcast
Host
michaelschneiders - BRAIN Biotech AG Financial Results H1 2022 / 23 | Steady Growth, Strategy, and Future Outlook with CFO -%sitename%

Michael Schneiders
CFO | BRAIN Biotech AG​

Linkedin Envelope
Share
T&C:

This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Continuing the Journey: More Presentations

Discover Additional Elevator Pitches

Release Date

May 25, 2023

Duration

11:49

Director

Reviews for BRAIN Biotech AG Financial Results H1 2022 / 23 | Steady Growth, Strategy, and Future Outlook with CFO
There are currently no reviews for BRAIN Biotech AG Financial Results H1 2022 / 23 | Steady Growth, Strategy, and Future Outlook with CFO
COMPANIES:

Germany:

Austria:

Estonia:

Finland:

France:

Italy:

Poland:

Spain:

PRESENTATIONS:
INDUSTRIES:
Linkedin Twitter Instagram Podcast Envelope Whatsapp

(c) seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESG 

Unlock the insights of top publicly listed companies with seat11a.com

Elevate your understanding with powerful Elevator Pitches, Deep-Dive Presentations, and in-depth Financial Analysis

Scroll to top